Ocean Biomedical, Inc. cash flow statement OCEA

Annual Quarterly

In fiscal 2024, which ended Dec 31, 2024, Ocean Biomedical, Inc. used $4.2 million of cash from operations, up 55.7% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2025
Mar 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating
Operating cash flow
-4
+44.2%
-4
+55.7%
-9
-849.5%
-1
Investing
Investing cash flow
—
—
—
-2
Financing
Short-term debt issued
—
—
8
—
Short-term debt repaid
—
—
2
—
Financing cash flow
1
3
-67.3%
10
+975.4%
1
Change in cash
Net change in cash
0
+21.1%
-1
-180.4%
1
+3830.8%
-0
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OCEA (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1869974
Former names
Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.